



November 10, 2023

✓ **BSE Limited**

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 ('Listing Regulations').

We are pleased to enclose a Press release regarding the Company having partnered with Amman Pharmaceuticals Industries, a leading pharmaceutical manufacturer with operations across the MENA region and other global markets, for exclusive marketing and commercialization of Ranibizumab, a biosimilar of Lucentis[®], in the Middle East region, including select territories of Jordan, Saudi Arabia, UAE, Iraq, Lebanon, and other GCC countries.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl: a/a

Lupin and Amman Pharma Sign Exclusive Licensing and Supply Agreement for Ranibizumab Biosimilar

Pioneering access to this complex ophthalmic biosimilar medicine in the MENA Region

Mumbai, Jordan, November 10, 2023: Global Pharma major Lupin Limited (Lupin) has partnered with Amman Pharmaceuticals Industries (Amman Pharma), a leading pharmaceutical manufacturer with operations across the MENA region and other global markets, for exclusive marketing and commercialization of Ranibizumab, a biosimilar of Lucentis®, in the Middle East region, including select territories of Jordan, Saudi Arabia, UAE, Iraq, Lebanon, and other GCC countries. Both Lupin and Amman Pharma are united in their mission to provide innovative, high-quality healthcare solutions to patients in the MENA region.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV).

“Our aim is to be at the forefront of transforming patient’s lives and building a healthier, brighter future for all. We are excited about the partnership with Amman Pharma to bring Ranibizumab to the MENA region,” said **Nilesh Gupta, Managing Director, Lupin**.

“We aim to empower patients by offering timely and widespread access to cutting-edge biologic medication at affordable costs. Our successful development of biosimilar Ranibizumab stands as testament to this commitment,” said **Dr. Cyrus Karkaria, President Biotechnology, Lupin**. “Our mission in collaborating with Amman Pharma is to provide patients with advanced biologics that hold the promise of reshaping their health journey.”

Dr. Fadi Alatrash, General Manager of Amman Pharma said, “We are proud to partner with Lupin, a world-leading biopharmaceutical company, to market and commercialize Ranibizumab. This partnership is aligned with our mission to provide high-quality products and access to advanced biosimilars to patients in the region. It also expands our biosimilar portfolio and strengthens our position in the niche Ophthalmology market.”

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on:

LinkedIn: <https://www.linkedin.com/company/lupin>

Twitter: <https://twitter.com/LupinGlobal>

Facebook: <http://www.facebook.com/LupinWorld/>

About Amman Pharma

Amman Pharmaceutical Industries (Amman Pharma) is one of the leading and fastest growing pharmaceutical manufacturers with operations across the MENA region and other global markets. Amman Pharma was established in 1989 as one of the first pharmaceutical companies in the MENA region to pioneer the production and commercialization of niche branded generics in the therapeutic areas of Ophthalmology, ENT, Respiratory, and Dermatology. Headquartered in Amman, Jordan, Amman Pharma markets a wide range of generic and biotech products in more than 30 markets in MENA region and globally.

For more information, please visit: www.ammanpharma.com

Follow us on:

LinkedIn: <https://www.linkedin.com/company/aman-pharmaceutical-industries>

Facebook: <https://www.facebook.com/amanpharma>

Instagram: https://www.instagram.com/aman_pharma/

For further information or queries please contact –

Shweta Munjal

Vice President & Global Head – Corporate Communications & Sustainability

Email: shwetamunjal@lupin.com